SCHEMBL15364728

SCHEMBL15364728

Nc1cccc(-c2ccncc2)c1N

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 1/20 0.51
ATAD2 Q6PL18 1/20 0.49
MAPT P10636 4/20 0.47
ACE2 Q9BYF1 1/20 0.46
ALDH1A1 P00352 3/20 0.43
HSD17B10 Q99714 1/20 0.43
PIK3CD O00329 1/20 0.43
JAK2 O60674 1/20 0.42
LMNA P02545 3/20 0.42
NOTUM Q6P988 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
GFER P55789 1/20 0.40
ADORA2A P29274 2/20 0.40
ADORA1 P30542 2/20 0.40
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
AURKB Q96GD4 1/20 0.40
INCENP Q9NQS7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30777517 0.89 MAPT (0.52) IMPDH2ATAD2MAPTACE2ALDH1A1
SCHEMBL30719314 0.84 MAPT (0.50) IMPDH2ATAD2MAPTALDH1A1PIK3CD
SCHEMBL21464156 0.84 BTK (0.42) IMPDH2ATAD2MAPTACE2ALDH1A1
SCHEMBL29450623 0.82 ALDH1A1 (0.65) IMPDH2ATAD2MAPTACE2ALDH1A1
SCHEMBL396362 0.82 ALDH1A1 (0.65) IMPDH2ATAD2MAPTACE2ALDH1A1
SCHEMBL8115984 0.81 IMPDH2 (0.59) IMPDH2ATAD2MAPTACE2ALDH1A1
Hydrochloric Acid SCHEMBL3381632 0.80 ALDH1A1 (0.62) IMPDH2ATAD2MAPTACE2ALDH1A1
SCHEMBL169282 0.79 ALDH1A1 (0.68) MAPTALDH1A1HSD17B10SMN1; SMN2NPC1
SCHEMBL29564016 0.79 ALDH1A1 (0.68) MAPTALDH1A1HSD17B10SMN1; SMN2NPC1
SCHEMBL1253847 0.79 MAPT (0.50) IMPDH2ATAD2MAPTACE2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115215861-B Aromatic heterocycle substituted alkyne compound and preparation method and application thereof 上海翊石医药科技有限公司 2024-03-15 CN disclosed
CN-115215861-A Aromatic heterocycle substituted alkyne compound and preparation method and application thereof 上海翊石医药科技有限公司 2022-10-21 CN disclosed
US-20200155525-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF SAMUMED, LLC 2020-05-21 US disclosed
US-20200155525-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF SAMUMED, LLC 2020-05-21 US disclosed
US-10654832-B2 3-(benzoimidazol-2-YL)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof SAMUMED, LLC (US) 2020-05-19 US disclosed
US-10654832-B2 3-(benzoimidazol-2-YL)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof SAMUMED, LLC (US) 2020-05-19 US disclosed
US-20190352279-A1 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2019-11-21 US disclosed
US-20190352279-A1 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2019-11-21 US disclosed
US-10392383-B2 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof SAMUMED, LLC (US) 2019-08-27 US disclosed
EP-2770994-B1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF SAMUMED LLC (US) 2019-08-21 EP disclosed
US-20140194441-A1 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF SAMUMED, LLC (US) 2014-07-10 US disclosed
US-20140005383-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF MED-PATHWAYS II LIMITED (VG) 2014-01-02 US disclosed
US-8618128-B1 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof SAMUMED, LLC (US) 2013-12-31 US disclosed
CN-103476767-A Heterocyclic compounds as PI3 kinase inhibitors HOFFMANN LA ROCHE 2013-12-25 CN disclosed
WO-2013166396-A2 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF SAMUMED, LLC (US) 2013-11-07 WO disclosed
WO-2013166396-A2 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF SAMUMED, LLC (US) 2013-11-07 WO disclosed
US-20130296302-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF SAMUMED, LLC (US) 2013-11-07 US disclosed
US-20130296302-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF SAMUMED, LLC (US) 2013-11-07 US disclosed
US-20130296302-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF SAMUMED, LLC (US) 2013-11-07 US disclosed
CN-102076813-A organic electroluminescent device MERCK PATENT GMBH 2011-05-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190352279-A1 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A IMPDH2 1035/4885ATAD2 2813/4885MAPT 134/4885
US-10392383-B2 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof WNT1, WNT3, WNT3A IMPDH2 1978/4885ATAD2 1947/4885MAPT 3150/4885
US-20140005383-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF COL1A1, NOX4, FGF1 IMPDH2 2520/4885ATAD2 3586/4885MAPT 107/4885
US-20130296302-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF COL1A1, NOX4, FGF1 IMPDH2 2520/4885ATAD2 3586/4885MAPT 107/4885
US-20140194441-A1 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A IMPDH2 1035/4885ATAD2 2813/4885MAPT 134/4885
US-10654832-B2 3-(benzoimidazol-2-YL)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof WNT1, WNT3, WNT3A IMPDH2 1035/4885ATAD2 2813/4885MAPT 134/4885
US-20200155525-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF COL1A1, NOX4, FGF1 IMPDH2 2520/4885ATAD2 3586/4885MAPT 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.